在近期三生制药、石药集团拿下大额BD交易后，创新药板块价值获得市场认可，二级市场行情持续火爆，聚焦创新药产业的恒生医药ETF（159892）年内涨幅超55%，科创医药ETF基金（588130）自5月底上市以来的涨幅超7%。据先声药业6月16日公告，公司旗下的抗肿瘤创新药公司先声再明与美国NextCure订立许可协议并建立战略合作关系，共同开发针对CDH6靶点的新型抗体药物偶联物（ADC）新药...
Source Link在近期三生制药、石药集团拿下大额BD交易后，创新药板块价值获得市场认可，二级市场行情持续火爆，聚焦创新药产业的恒生医药ETF（159892）年内涨幅超55%，科创医药ETF基金（588130）自5月底上市以来的涨幅超7%。据先声药业6月16日公告，公司旗下的抗肿瘤创新药公司先声再明与美国NextCure订立许可协议并建立战略合作关系，共同开发针对CDH6靶点的新型抗体药物偶联物（ADC）新药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.